GlassScriptPhysician profile
Andrew J Luisi
NPI 1467428599
$1,577.77
in general payments reported to CMS, 2019-2025
19 companies · $342 in 2025
The $342 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $55.01 · 2021: $79.35 · 2022: $157 · 2023: $472 · 2024: $267 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,080.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $251.77 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $220.70 | 2022-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $144.50 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.47 | 2023-2025 | Jardiance |
| Amgen INC. | $137.91 | 2019-2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $130.14 | 2023-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $111.62 | 2021-2023 | Camzyos |
| Janssen Pharmaceuticals, INC | $78.20 | 2023 | Xarelto |
| Lantheus Medical Imaging, INC. | $76.07 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $47.48 | 2019-2023 | |
| Biotronik INC. | $39.44 | 2019 | |
| Edwards Lifesciences Corporation | $39.05 | 2025 | Sapien 3 Ultra Resilia |
| Astrazeneca Pharmaceuticals LP | $35.25 | 2023-2024 | Farxiga |
| Esperion Therapeutics, INC. | $31.25 | 2021-2024 | Nexletol |
| Medtronic, INC. | $28.05 | 2023 | Onyx Frontier |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medicomp INC | $17.32 | 2023 | Telepatch Cardiac Monitor |
| Novo Nordisk INC | $16.76 | 2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $16.11 | 2019 | |
| Boston Scientific Corporation | $14.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Luisi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.